Hinge Health (HNGE) CEO converts and sells 166,670 shares in Rule 10b5-1 plan trades

Rhea-AI Filing Summary

Hinge Health, Inc. CEO, Co‑Founder, director and 10% owner reported insider transactions dated December 15, 2025. On that date, he converted 166,670 shares of Class B common stock into Class A common stock at an exercise price of $0, then disposed of the same 166,670 Class A shares in open‑market sales.

The first sale covered 161,250 Class A shares at a weighted average price of $48.5031, within a range of $47.98 to $48.96. The second sale covered 5,420 shares at a weighted average price of $49.2962, within a range of $49.00 to $49.58. All sales were made under a Rule 10b5‑1 trading plan adopted on September 11, 2025.

After these transactions, he beneficially owned 14,543,427 shares of Class B common stock directly, plus 515,705 Class B shares and 35,470 Class A shares indirectly through his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perez Daniel Antonio

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CA 94015

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Co-Founder

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/15/2025		C		166,670	A	$0	166,760	D
Class A Common Stock	12/15/2025		S(1)		161,250	D	$48.5031(2)	5,420	D
Class A Common Stock	12/15/2025		S(1)		5,420	D	$49.2962(3)	0	D
Class A Common Stock								35,470	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Class B Common Stock	(4)	12/15/2025		C			166,670	(4)	(4)	Class A Common Stock	166,670	$0	14,543,427	D
Class B Common Stock	(4)							(4)	(4)	Class A Common Stock	515,705		515,705	I	By Spouse

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $47.98 and the highest price at which shares were sold was $48.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $49.00 and the highest price at which shares were sold was $49.58. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.

	/s/ James Budge, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Hinge Health (HNGE) report for its CEO on December 15, 2025?

The filing shows that the CEO converted 166,670 shares of Class B common stock into Class A common stock at an exercise price of $0, then sold the same 166,670 Class A shares in market transactions on December 15, 2025.

How many Hinge Health (HNGE) shares did the CEO sell and at what prices?

The CEO sold 161,250 Class A shares at a weighted average price of $48.5031 (range $47.98–$48.96) and 5,420 Class A shares at a weighted average price of $49.2962 (range $49.00–$49.58).

Was the Hinge Health CEO’s stock sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on September 11, 2025, which is described as a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c).

What Hinge Health shares does the CEO beneficially own after these transactions?

Following the reported transactions, he beneficially owned 14,543,427 shares of Class B common stock directly, plus 515,705 Class B shares and 35,470 Class A shares indirectly through his spouse.

What types of Hinge Health stock classes are involved in this insider filing?

The filing involves both Class A common stock and Class B common stock. Each share of Class B common stock is convertible into one share of Class A common stock at any time at the holder’s election or automatically upon certain transfers or events described in the company’s amended and restated certificate of incorporation.

How are the sale prices for the Hinge Health CEO’s trades described?

The sale prices are reported as weighted average sale prices, with the filing also disclosing the lowest and highest prices within each range. It notes that full information on the number of shares sold at each separate price in the ranges is available upon request to the company, its stockholders, or the SEC staff.